|
Status |
Public on Sep 01, 2016 |
Title |
Differentially expressed genes in certinib-resistant NB-1 xenografts |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
The goal of this study is to elucidate the molecular mechanism that allowed NB-1 xenograft tumors to grow out in the presence of continued ALK inhibition. Poly(A)-selected RNA was extracted from tissues of NB-1 tumors that progressed on ceritinib treatment and those treated with a vehicle to identify differentially expressed genes between these two groups.
|
|
|
Overall design |
mRNA profiles of NB-1 xenograft tumors that progressed on ceritinib treatment and those treated with a vehicle were generated by RNA sequencing, in duplicate, using Illumina HiSeq 2500.
|
|
|
Contributor(s) |
Li F, Ruddy DA, Rakiec DP |
Citation(s) |
28425916 |
Submission date |
Jun 01, 2016 |
Last update date |
Sep 02, 2019 |
Contact name |
Fang Li |
Organization name |
Novartis Institutes for BioMedical Research, Inc.
|
Street address |
250 Massachusetts Avenue
|
City |
Cambridge |
State/province |
MA |
ZIP/Postal code |
02139 |
Country |
USA |
|
|
Platforms (1) |
GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
Samples (4)
|
|
Relations |
BioProject |
PRJNA324126 |
SRA |
SRP075983 |